Chardan Capital Forecasts Strong Price Appreciation for SAB Biotherapeutics (NASDAQ:SABS) Stock

SAB Biotherapeutics (NASDAQ:SABS) had its price target increased by equities research analysts at Chardan Capital from $12.00 to $14.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Chardan Capital’s price target would suggest a potential upside of 206.01% from the company’s current price.

Other research analysts have also issued reports about the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of SAB Biotherapeutics in a research report on Monday, December 29th. UBS Group started coverage on SAB Biotherapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $7.00 price objective for the company. HC Wainwright reduced their price objective on SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday. Guggenheim began coverage on SAB Biotherapeutics in a report on Friday, December 19th. They set a “buy” rating and a $15.00 price objective on the stock. Finally, Wall Street Zen raised SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, SAB Biotherapeutics currently has an average rating of “Moderate Buy” and an average price target of $10.00.

SAB Biotherapeutics Price Performance

SABS traded up $0.48 on Wednesday, reaching $4.58. The company had a trading volume of 2,522,939 shares, compared to its average volume of 455,720. SAB Biotherapeutics has a 52-week low of $1.00 and a 52-week high of $6.60. The company has a market cap of $217.82 million, a price-to-earnings ratio of -1.96 and a beta of 0.59. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.50 and a current ratio of 10.49. The business has a 50 day simple moving average of $3.98 and a 200 day simple moving average of $3.33.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.30). As a group, sell-side analysts anticipate that SAB Biotherapeutics will post -3.69 EPS for the current year.

Hedge Funds Weigh In On SAB Biotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. HB Wealth Management LLC purchased a new stake in shares of SAB Biotherapeutics during the third quarter valued at approximately $618,000. Persistent Asset Partners Ltd bought a new stake in SAB Biotherapeutics during the 4th quarter valued at $74,000. Spruce Street Capital LP purchased a new stake in SAB Biotherapeutics during the 4th quarter valued at $8,222,000. State Street Corp bought a new stake in SAB Biotherapeutics in the 4th quarter worth $49,000. Finally, State of Wyoming bought a new stake in SAB Biotherapeutics in the 4th quarter worth $34,000. 7.82% of the stock is currently owned by institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.